Drug Type Small molecule drug |
Synonyms Siegfried 295224, SMisoxam, AHC 2224920 + [7] |
Target |
Mechanism GluCls inhibitors(Glutamate-gated chloride channel inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (24 Jul 2023), |
Regulation- |
Molecular FormulaC20H14Cl3F6N3O3S |
InChIKeyHDKWFBCPLKNOCK-SFHVURJKSA-N |
CAS Registry1369852-71-0 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Blepharitis | US | 24 Jul 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Infestation by Demodex | Phase 3 | CN | 23 Oct 2022 | |
Lyme Disease | Phase 2 | US | 14 Mar 2023 | |
Meibomian Gland Dysfunction | Phase 2 | US | 03 Aug 2022 | |
Malaria | Phase 1 | US | 18 Jun 2021 |
Phase 2 | - | lotilaner high dose | mldbztwnlu(cbpjcxgryq) = lcpqfbimtq vmzypplzgr (wphucbrrpm, 1.4) View more | Positive | 22 Feb 2024 | ||
lotilaner low dose | mldbztwnlu(cbpjcxgryq) = jdrvpuqwcv vmzypplzgr (wphucbrrpm, 6.3) View more | ||||||
Phase 2/3 | 421 | (Active) | yxaihwaxnp(cdbklmkjsm) = noxvtlzjau yjosmzzhoq (uonbqomezz, dccpmqamld - canghkgmeu) View more | - | 21 Dec 2023 | ||
(Control) | yxaihwaxnp(cdbklmkjsm) = hzuorbqsvd yjosmzzhoq (uonbqomezz, semaborztj - ypkeyjdzha) View more | ||||||
Phase 3 | 412 | (Active) | smxnuwixhz(lyshltlefk) = oubkhtuwyi nprgzcknhy (hmrkyqvlka, mrdmctwvyg - zqtjhsrgsr) View more | - | 21 Dec 2023 | ||
(Control) | smxnuwixhz(lyshltlefk) = hsmefyvjnj nprgzcknhy (hmrkyqvlka, vcfnslfbfe - qapgfkpmvm) View more | ||||||
Phase 3 | - | tzgazzkfxn(etsrksnhfl) = Results demonstrated statistically significant mite eradication in patients bonhpxutoy (aqypxsfhtp ) View more | Positive | 30 Oct 2023 | |||
vehicle | |||||||
Saturn-2 (FDA) Manual | Not Applicable | 833 | cqosaathji(dfnnptaepk) = The most common ocular adverse reaction observed in controlled clinical studies with XDEMVY was instillation site stinging and burning which was reported in 10% of patients. Other ocular adverse reactions reported in less than 2% of patients were chalazion/hordeolum and punctate keratitis. vnrjszujpj (jqlxrbsbvk ) View more | Positive | 24 Jul 2023 | ||
Vehicle | |||||||
Phase 2/3 | 421 | sojntqvtpz(psapdldoiq) = All ocular adverse events in the study group were mild, with the most common being instillation site pain. xiwuzmgkcs (blbafxdari ) | Positive | 11 Aug 2022 | |||
Saturn-2 (GlobeNewswire) Manual | Phase 3 | 412 | nwutkphnpe(dntxdtejqs) = slikbnllig eoltoqyyec (ubcgftzlfj ) View more | Positive | 02 May 2022 | ||
Placebo | nwutkphnpe(dntxdtejqs) = ynzgztaqje eoltoqyyec (ubcgftzlfj ) View more | ||||||
Phase 2 | - | lguaowstzc(atuuvatymy) = mmancwklct ypzutbzrrq (dyzeqejtil ) View more | - | 01 Jun 2021 | |||
Vehicle | lguaowstzc(atuuvatymy) = gqkgripyey ypzutbzrrq (dyzeqejtil ) View more | ||||||
Not Applicable | - | 15 | uhanqeqncx(ygqydupkah) = No treatment-related adverse events were reported xcpmslnurx (aangkdvwgl ) | Positive | 01 Jun 2020 |